JP2024515720A5 - - Google Patents

Info

Publication number
JP2024515720A5
JP2024515720A5 JP2023564657A JP2023564657A JP2024515720A5 JP 2024515720 A5 JP2024515720 A5 JP 2024515720A5 JP 2023564657 A JP2023564657 A JP 2023564657A JP 2023564657 A JP2023564657 A JP 2023564657A JP 2024515720 A5 JP2024515720 A5 JP 2024515720A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
test
composition
combination
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025986 external-priority patent/WO2022226334A1/en
Publication of JP2024515720A publication Critical patent/JP2024515720A/ja
Publication of JP2024515720A5 publication Critical patent/JP2024515720A5/ja
Pending legal-status Critical Current

Links

JP2023564657A 2021-04-23 2022-04-22 筋ジストロフィーを治療するための製品及び方法 Pending JP2024515720A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178648P 2021-04-23 2021-04-23
US63/178,648 2021-04-23
PCT/US2022/025986 WO2022226334A1 (en) 2021-04-23 2022-04-22 Products and methods for treating muscular dystrophy

Publications (2)

Publication Number Publication Date
JP2024515720A JP2024515720A (ja) 2024-04-10
JP2024515720A5 true JP2024515720A5 (cg-RX-API-DMAC7.html) 2025-04-28

Family

ID=81854546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564657A Pending JP2024515720A (ja) 2021-04-23 2022-04-22 筋ジストロフィーを治療するための製品及び方法

Country Status (6)

Country Link
US (1) US20240200066A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326752A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515720A (cg-RX-API-DMAC7.html)
AU (1) AU2022262420A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226334A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230279397A1 (en) 2022-03-04 2023-09-07 Locanabio, Inc. Compositions and methods comprising engineered short nuclear rna (snrna)
WO2024192281A2 (en) * 2023-03-15 2024-09-19 Regenxbio Inc. Exon skipping gene therapy constructs, vectors and uses thereof
WO2025179121A1 (en) * 2024-02-21 2025-08-28 Research Institute At Nationwide Children's Hospital Exon 17-targeted nucleic acids, compositions, and methods for treatment of dystrophin-based myopathies
CN120130955B (zh) * 2025-05-16 2025-09-09 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) 一种多源数据融合的肌少症检测系统及方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69433922T2 (de) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
ES2627917T3 (es) * 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
EP3133160B1 (en) * 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
US20140080896A1 (en) * 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
CA2957661A1 (en) * 2014-08-09 2016-02-18 Kevin FLANIGAN Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
EP3746557A1 (en) * 2018-01-31 2020-12-09 The Board Of Regents Of The University Of Texas System Compositions and methods for correcting dystrophin mutations in human cardiomyocytes
JP7478675B2 (ja) * 2018-06-08 2024-05-07 ノバルティス アーゲー 薬物製品の効力を測定するための細胞ベースアッセイ
US20220282247A1 (en) * 2019-08-02 2022-09-08 Research Institute At Nationwide Children's Hospital Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies

Similar Documents

Publication Publication Date Title
Khoshandam et al. Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine
JP5711666B2 (ja) 白血球への効率的輸送
Kabanov et al. Pluronic block copolymers for gene delivery
ES2502915T3 (es) Composición que comprende un ARN(m) complejado y un ARNm desnudo para proporcionar o mejorar la respuesta inmunoestimuladora en un mamífero y usos de la misma
HRP20250932T1 (hr) Dostava mišićno specifičnog mikrodistrofina putem vektora adeno-asociranog virusa za liječenje mišićne distrofije
JP2022544627A5 (cg-RX-API-DMAC7.html)
EP4218828A3 (en) Adeno-associated virus variant capsids and methods of use thereof
EP0871491A2 (en) Polymers
EP3416634A1 (en) Immunomodulatory agents and methods of use thereof
KR102075393B1 (ko) 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물
EP2547345A1 (en) Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
JP2024527340A5 (cg-RX-API-DMAC7.html)
JP2024540994A5 (cg-RX-API-DMAC7.html)
US20240165222A1 (en) Vaccine composition for preventing sars-cov-2
JP2021513365A (ja) スクレロスチンに対するアプタマー及びその使用
KR20200041310A (ko) 인간에서의 aav 유전자 요법을 위한 수단 및 방법
JP2023543029A5 (cg-RX-API-DMAC7.html)
KR20220110523A (ko) Ilt7 결합 단백질을 사용하는 치료 방법
CN114276419B (zh) 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
JP2022532098A5 (cg-RX-API-DMAC7.html)
CN103961687A (zh) G蛋白偶联受体相互作用蛋白2在制备抗炎症药物中的应用
WO2025043010A1 (en) Nucleic acid compositions for the generation of a zika virus-like particle
US20230019602A1 (en) Methods for treatment of motor neuron diseases
CA2423045A1 (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
US20230303598A1 (en) Bioinspired lipid derivatives and uses thereof